Cargando…

Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy has substantially improved the overall survival (OS) in patients with non-small-cell lung cancer (NSCLC); however, its response rate is still modest. In this study, we developed a machine learning-based platform, namely the Cytokine-based ICI Res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Feifei, Azuma, Koichi, Nakahara, Yoshiro, Saito, Haruhiro, Matsuo, Norikazu, Tagami, Tomoyuki, Kouro, Taku, Igarashi, Yuka, Tokito, Takaaki, Kato, Terufumi, Kondo, Tetsuro, Murakami, Shuji, Usui, Ryo, Himuro, Hidetomo, Horaguchi, Shun, Tsuji, Kayoko, Murotani, Kenta, Ban, Tatsuma, Tamura, Tomohiko, Miyagi, Yohei, Sasada, Tetsuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347453/ https://www.ncbi.nlm.nih.gov/pubmed/37433717 http://dx.doi.org/10.1136/jitc-2023-006788

Ejemplares similares

Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model
por: Azuma, Koichi, et al.
Publicado: (2022)

Exhaustion of CAR T cells: potential causes and solutions
por: Kouro, Taku, et al.
Publicado: (2022)

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
por: Bai, Hua, et al.
Publicado: (2020)

Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
por: Xie, Lin, et al.
Publicado: (2021)

Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
por: Wang, Haizhou, et al.
Publicado: (2022)

Multiple TMA-aided CRISPR/Cas13a platform for highly sensitive detection of IL-15 to predict immunotherapeutic response in nasopharyngeal carcinoma
por: Wu, Ya-Xian, et al.
Publicado: (2023)

Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination
por: Sun, Zhijia, et al.
Publicado: (2023)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
por: Shibata, Yosuke, et al.
Publicado: (2023)

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
por: Keegan, Alissa, et al.
Publicado: (2020)

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
por: Thompson, Jeffrey C, et al.
Publicado: (2020)

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
por: Vaidya, Pranjal, et al.
Publicado: (2020)

KALRN mutations promote antitumor immunity and immunotherapy response in cancer
por: Li, Mengyuan, et al.
Publicado: (2020)

Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma
por: Liu, Fangming, et al.
Publicado: (2020)

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
por: Bai, Xue, et al.
Publicado: (2020)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
por: Chardin, David, et al.
Publicado: (2020)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
por: Yao, Yao, et al.
Publicado: (2020)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
por: Mazzotta, Marco, et al.
Publicado: (2020)

Is there a link between very early changes of primary and secondary lymphoid organs in (18)F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?
por: Seith, Ferdinand, et al.
Publicado: (2020)

Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets
por: Oldham, Robyn A A, et al.
Publicado: (2020)

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
por: Hensler, Michal, et al.
Publicado: (2020)

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Stromal LAG-3(+) cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture
por: Zeng, Han, et al.
Publicado: (2020)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
por: Jiang, Xiaoyu, et al.
Publicado: (2020)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma
por: Wang, Yuelong, et al.
Publicado: (2020)

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
por: Cassetta, Luca, et al.
Publicado: (2020)

CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage
por: Zhu, Yanfang Peipei, et al.
Publicado: (2020)

Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients
por: Xiong, Ying, et al.
Publicado: (2020)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9t6chhl201s6rhook30hpaejfk